Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 55 (6), 1428-40

HCV and the Hepatic Lipid Pathway as a Potential Treatment Target

Affiliations
Review

HCV and the Hepatic Lipid Pathway as a Potential Treatment Target

Margaret F Bassendine et al. J Hepatol.

Abstract

Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.

Similar articles

See all similar articles

Cited by 24 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback